STOCK TITAN
  1. Home
  2. News
  3. CARA

Cara Therapeutics Inc - CARA STOCK NEWS

Welcome to our dedicated news page for Cara Therapeutics (Ticker: CARA), a resource for investors and traders seeking the latest updates and insights on Cara Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cara Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cara Therapeutics's position in the market.

News
Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Cara Therapeutics, Inc. (CARA) to present at the 23rd Annual Needham Virtual Healthcare Conference. The President and CEO will discuss the company's innovative pruritus treatment approach. Webcast details are available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.1%
Tags
conferences
-
News
Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024
Rhea-AI Summary
Cara Therapeutics, Inc. (CARA) to host a virtual key opinion leader event discussing neuropathic pruritus treatment landscape. The event will feature experts in the field and highlight oral difelikefalin in notalgia paresthetica.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.05%
Tags
conferences
-
News
Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Cara Therapeutics prioritizes late-stage development of oral difelikefalin for notalgia paresthetica, completes enrollment ahead of schedule, extends cash runway, and announces financial results for Q4 and full year 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.98%
Tags
earnings
News
Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024
Rhea-AI Summary
Cara Therapeutics, Inc. (CARA) will host a conference call on March 4, 2024, to report Q4 and full year 2023 financial results. Registrants can access the call via webcast or dial-in numbers. The event will provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.58%
Tags
earnings
-
News
Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026
Rhea-AI Summary
Cara Therapeutics, Inc. announced a strategic shift to focus on the oral difelikefalin Phase 2/3 clinical program in notalgia paresthetica (NP) and reduce operating expenses, extending the cash runway into 2026. The company will discontinue the Phase 3 program in advanced chronic kidney disease (CKD) and implement a workforce reduction of up to 50%. The decision is expected to allow the completion of the NP clinical program and reach key value-inflection milestones. The Phase 2/3 clinical program for NP is progressing ahead of projections, with a data readout expected in Q3 2024. The company also announced the departure of Frédérique Menzaghi, Ph.D., Chief Scientific Officer and SVP of Research & Development, effective February 2, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
none
-
News
Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis
Rhea-AI Summary
Cara Therapeutics, a biopharmaceutical company (Nasdaq: CARA), announced the discontinuation of its clinical program for oral difelikefalin as an adjunct to topical corticosteroids (TCS) for pruritus associated with atopic dermatitis. The company's late-stage programs for pruritus associated with notalgia paresthetica and advanced chronic kidney disease continue to enroll as planned, with key data readouts expected in the second half of 2024. Cara expects to end 2023 with approximately $100 million in cash.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-48.86%
Tags
none
News
Cara Therapeutics Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Cara Therapeutics, Inc. (Nasdaq: CARA) announced a non-dilutive financing agreement with HealthCare Royalty for up to $40 million, extending cash runway into 2025. Key data readouts for all three late-stage oral difelikefalin clinical programs are anticipated within the current financial runway. The company also reported 3Q23 total revenue of $4.9M, including collaborative revenue of $1.9M from the Company’s share of profit of KORSUVA® (difelikefalin) injection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.2%
Tags
earnings
-
News
Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare Royalty
Rhea-AI Summary
Cara Therapeutics has entered into a Royalty Interest Purchase and Sale Agreement with HealthCare Royalty (HCRx) to support the ongoing clinical development of its oral difelikefalin pipeline. The agreement provides non-dilutive capital and is expected to extend Cara's cash runway into 2025. Under the agreement, Cara will receive an initial payment of $17.5 million, with an additional payment of $20.0 million upon difelikefalin receiving a certain minimum price in Germany. If specified performance levels are achieved in Japan, Cara will receive a $2.5 million milestone payment. HCRx will receive all royalties from ex-U.S. license agreements, with payments capped at 2.0x before the end of 2029.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.65%
Tags
none
-
News
Cara Therapeutics to Announce Third Quarter 2023 Financial Results on November 13, 2023
Rhea-AI Summary
Cara Therapeutics to host conference call and report Q3 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.65%
Tags
earnings
News
Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis Patients
Rhea-AI Summary
Cara Therapeutics receives $1.5 million milestone payment upon approval of KORSUVA® IV Injection Syringe in Japan for pruritus treatment in hemodialysis patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.4%
Tags
none
Stock CARA logo
Cara Therapeutics Inc

Nasdaq:CARA

CARA Rankings

#4893 Ranked by Market Cap
#5448 Ranked by Stock Gains
N/A Ranked by Dividends

CARA Stock Data

41.76M
39.35M
14.58%
45.49%
4.71%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Stamford

About CARA

cara therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat pain, inflammation and pruritus. cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. cara's most advanced patented compound, cr845, is currently undergoing clinical testing for acute pain and uremic pruritus. this compound possesses analgesic, anti-inflammatory and antipruritic activities appropriate for multiple therapeutic applications. in addition, cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.